499:
29:
223:
Sevindik, Ömür Gökmen; Chen, Chang; Yang, Jing; Farooqui, Mohammed Z.H.; Paszkiewicz-Kozik, Ewa (1 June 2023). "BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
394:
Woyach, Jennifer A.; Stephens, Deborah M.; Flinn, Ian W.; Bhat, Seema A.; Savage, Ronald E.; Chai, Feng; Eathiraj, Sudharshan; Reiff, Sean D.; Muhowski, Elizabeth M.; Granlund, Lindsey; Szuszkiewicz, Lyndsey; Wang, Wayne; Schwartz, Brian; Ghori, Razi; Farooqui, Mohammed Z. H.; Byrd, John C. (6
300:
Reiff, Sean D.; Mantel, Rose; Smith, Lisa L.; Greene, J.T.; Muhowski, Elizabeth M.; Fabian, Catherine A.; Goettl, Virginia M.; Tran, Minh; Harrington, Bonnie K.; Rogers, Kerry A.; Awan, Farrukh T.; Maddocks, Kami; Andritsos, Leslie; Lehman, Amy M.; Sampath, Deepa; Lapalombella, Rosa; Eathiraj,
352:
Woyach, Jennifer A.; Flinn, Ian W.; Awan, Farrukh T.; Eradat, Herbert; Brander, Danielle; Tees, Michael; Parikh, Sameer A.; Phillips, Tycel J.; Ghori, Razi; Reddy, Nishitha M.; Farooqui, Mohammed Z.H.; Byrd, John C.; Stephens, Deborah M. (15 November 2022).
355:"Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study"
261:"P682: Nemtabrutinib (Mk-1026), A Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase for B-Cell Malignancies: Efficacy and Safety of the Phase 2 Dose-Expansion Bellwave-001 Study"
259:
Woyach, J.; Flinn, I. W.; Awan, F. T.; Eradat, H.; Brander, D.; Tees, M.; Parikh, S. A.; Phillips, T.; Wang, W.; Reddy, N. M.; Farooqui, M. Z.; Byrd, J. C.; Stephens, D. M. (23 June 2022).
397:"First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma"
540:
559:
54:
564:
301:
Sudharshan; Abbadessa, Giovanni; Schwartz, Brian; Johnson, Amy J.; Byrd, John C.; Woyach, Jennifer A. (1 October 2018).
120:
589:
199:
206:
paid $ 2.7 billion to acquire the company ArQule and the drug, which is being investigated as a cancer treatment.
584:
533:
579:
569:
574:
526:
75:
475:
428:
376:
282:
241:
467:
420:
412:
334:
202:(BTK) inhibitor; unlike other BTK inhibitors it also works against some mutated forms of BTK.
84:
459:
404:
366:
324:
314:
272:
233:
145:
129:
237:
510:
329:
302:
277:
260:
203:
303:"The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation"
109:
553:
479:
447:
432:
380:
286:
245:
506:
408:
319:
198:(MK-1026, formerly ARQ 531) is a small molecule drug that works as a reversible
463:
371:
354:
181:
20:
471:
416:
396:
424:
338:
28:
498:
95:
514:
180:
144:
139:
119:
94:
74:
69:
53:
48:
40:
35:
108:
83:
534:
8:
19:
541:
527:
27:
448:"Merck will pay $ 2.7 billion for ArQule"
370:
328:
318:
276:
128:
215:
18:
7:
495:
493:
238:10.1200/JCO.2023.41.16_suppl.TPS7594
446:Lisa m. Jarvis (16 December 2019).
99:
278:10.1097/01.HS9.0000845612.25766.0c
14:
497:
165:
162:
156:
171:
150:
1:
513:. You can help Knowledge by
409:10.1158/2159-8290.CD-23-0670
320:10.1158/2159-8290.CD-17-1409
226:Journal of Clinical Oncology
365:(Supplement 1): 7004–7006.
224:without TP53 aberrations".
606:
560:Tyrosine kinase inhibitors
492:
452:C&EN Global Enterprise
140:Chemical and physical data
464:10.1021/cen-09748-buscon4
372:10.1182/blood-2022-163596
26:
200:Bruton's tyrosine kinase
509:-related article is a
232:(16_suppl): TPS7594.
565:Small-molecule drugs
23:
590:Pharmacology stubs
522:
521:
313:(10): 1300–1315.
193:
192:
16:Chemical compound
597:
585:Pyrrolopyridines
543:
536:
529:
501:
494:
484:
483:
443:
437:
436:
401:Cancer Discovery
395:November 2023).
391:
385:
384:
374:
349:
343:
342:
332:
322:
307:Cancer Discovery
297:
291:
290:
280:
256:
250:
249:
220:
188:
173:
167:
164:
158:
152:
132:
112:
102:
101:
87:
44:MK-1026; ARQ 531
31:
24:
22:
605:
604:
600:
599:
598:
596:
595:
594:
550:
549:
548:
547:
490:
488:
487:
445:
444:
440:
393:
392:
388:
351:
350:
346:
299:
298:
294:
258:
257:
253:
222:
221:
217:
212:
186:
176:
170:
161:
155:
135:
115:
98:
90:
65:
62:Investigational
17:
12:
11:
5:
603:
601:
593:
592:
587:
582:
577:
572:
567:
562:
552:
551:
546:
545:
538:
531:
523:
520:
519:
502:
486:
485:
438:
386:
344:
292:
251:
214:
213:
211:
208:
191:
190:
184:
178:
177:
174:
168:
159:
153:
148:
142:
141:
137:
136:
134:
133:
125:
123:
117:
116:
114:
113:
105:
103:
92:
91:
89:
88:
80:
78:
72:
71:
67:
66:
64:
63:
59:
57:
51:
50:
46:
45:
42:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
602:
591:
588:
586:
583:
581:
580:Benzaldehydes
578:
576:
573:
571:
570:Phenol ethers
568:
566:
563:
561:
558:
557:
555:
544:
539:
537:
532:
530:
525:
524:
518:
516:
512:
508:
503:
500:
496:
491:
481:
477:
473:
469:
465:
461:
457:
453:
449:
442:
439:
434:
430:
426:
422:
418:
414:
410:
406:
402:
398:
390:
387:
382:
378:
373:
368:
364:
360:
356:
348:
345:
340:
336:
331:
326:
321:
316:
312:
308:
304:
296:
293:
288:
284:
279:
274:
270:
266:
262:
255:
252:
247:
243:
239:
235:
231:
227:
219:
216:
209:
207:
205:
201:
197:
196:Nemtabrutinib
185:
183:
179:
149:
147:
143:
138:
131:
127:
126:
124:
122:
118:
111:
107:
106:
104:
97:
93:
86:
82:
81:
79:
77:
73:
68:
61:
60:
58:
56:
52:
47:
43:
39:
36:Clinical data
34:
30:
25:
21:Nemtabrutinib
575:Chloroarenes
515:expanding it
507:pharmacology
504:
489:
455:
451:
441:
400:
389:
362:
358:
347:
310:
306:
295:
268:
264:
254:
229:
225:
218:
195:
194:
85:2095393-15-8
55:Legal status
49:Legal status
271:: 578–579.
189: g·mol
70:Identifiers
41:Other names
554:Categories
458:(48): 13.
265:HemaSphere
210:References
182:Molar mass
130:JTZ51LIXN4
76:CAS Number
480:212811804
472:2474-7408
433:265032444
417:2159-8290
381:256785160
287:250001988
246:259080098
110:129045720
425:37930156
339:30093506
330:6261467
146:Formula
96:PubChem
478:
470:
431:
423:
415:
379:
337:
327:
285:
244:
187:478.93
505:This
476:S2CID
429:S2CID
377:S2CID
359:Blood
283:S2CID
242:S2CID
204:Merck
511:stub
468:ISSN
421:PMID
413:ISSN
335:PMID
121:UNII
460:doi
405:doi
367:doi
363:140
325:PMC
315:doi
273:doi
234:doi
100:CID
556::
474:.
466:.
456:97
454:.
450:.
427:.
419:.
411:.
403:.
399:.
375:.
361:.
357:.
333:.
323:.
309:.
305:.
281:.
267:.
263:.
240:.
230:41
228:.
163:Cl
160:23
154:25
542:e
535:t
528:v
517:.
482:.
462::
435:.
407::
383:.
369::
341:.
317::
311:8
289:.
275::
269:6
248:.
236::
175:4
172:O
169:4
166:N
157:H
151:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
